Market Overview

UPDATE: Morgan Stanley Cuts PT to $42 on MetLife Following Guidance

Related MET
The US Life Insurance Sector: 2 Stocks To Buy, 2 To Sell
How Recent Hurricanes And Earthquakes Can Actually Benefit Reinsurance Investors
Metlife Shows Rising Relative Price Performance; Still Shy Of Key Benchmark (Investor's Business Daily)

Morgan Stanley reiterated its Overweight rating on MetLife (NYSE: MET) but lowered its price target from $44 to $42.

Morgan Stanley noted, "MetLife's guidance was modestly disappointing, with both EPS and capital expectations running somewhat below our expectations. That said, their guidance is typically conservative (they typically hit at least the high end), and even with lowered numbers, the valuation multiple on stock is very low."

MetLife closed at $33.61 on Wednesday.

Latest Ratings for MET

Oct 2017Goldman SachsInitiates Coverage OnBuy
Oct 2017FBR CapitalDowngradesBuyNeutral
Oct 2017Morgan StanleyMaintainsEqual-Weight

View More Analyst Ratings for MET
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Price Target Intraday Update Analyst Ratings


Related Articles (MET)

View Comments and Join the Discussion!

Partner Center